The European Medicines Agency's key drug assessment committee has recommended marketing authorization for five new therapies, including a more convenient subcutaneous formulation of a proven multiple myeloma treatment. The positive opinions from the Committee for Medicinal Products for Human Use (CHMP) pave the way for broader treatment options across several disease areas, pending final approval by the European Commission.
The recommendations include a new, easier-to-administer version of Sanofi's Sarclisa (isatuximab). Currently given as an intravenous infusion, the CHMP has now endorsed a subcutaneous formulation. This method allows the drug to be injected under the skin, potentially cutting administration time from hours to minutes and improving the treatment experience for patients with relapsed and refractory multiple myeloma.
Alongside this, the committee recommended four entirely new medicines. These are Vivjoa (oteseconazole), for recurrent vulvovaginal candidiasis; Zavzpret (zavegepant), a nasal spray for acute migraine treatment; Epkinly (epcoritamab), a bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma; and Zynyz (retifanlimab), for metastatic or recurrent locally advanced Merkel cell carcinoma. Each drug represents a new therapeutic mechanism for its respective condition.
For patients, these CHMP endorsements signal near-term access to novel options. The subcutaneous Sarclisa could reduce clinic visits and enhance quality of life for myeloma patients. The new drugs address significant unmet needs: Vivjoa targets a specific type of recurrent fungal infection, Zavzpret offers an alternative non-oral pathway for migraine relief, Epkinly provides a new line of defense against aggressive lymphoma, and Zynyz introduces an immunotherapy for a rare, aggressive skin cancer.
The European Commission typically follows the CHMP's scientific recommendations and is expected to issue final decisions on all five therapies within approximately two months. If granted, these approvals will allow manufacturers to market the treatments across the European Union, giving healthcare providers and patients a wider arsenal to combat complex diseases.